 |
|
 |
|
 |
|
08:45 a.m 09:00 a.m. |
|
Congress Opening ceremony Fruchart J.-C. (France) |
09:00 a.m. 10:30 a.m. |
•
•
• |
ACADEMIC SESSION 1 Definitions, epidemiology and global risks of the metabolic syndrome Chair: C. Calvo (Chile) Prevalence, incidence and determinants of the metabolic syndrome M. Hermans (Belgium) Epidemiology of MS: lesson from PROCAM study E. Farinaro (Italy) Towards an unique definition for metabolic syndrome S. Smith (USA) |
10:30 a.m. 11:00 a.m. |
|
Coffee Break |
11:00 a.m. 12:30 p.m. |
•
•
•
• |
Symposium sponsored by SOLVAY PHARMACEUTICALS Type 2 Diabetes. Focus on microvascular complications Chair: J.-C. Fruchart (France) Diabetic retinopathy: targeting microvascular residual G. Crepaldi (Italy) Prevention of microvascular - associated complications of type 2 diabetes mellitus; the FIELD study A. Keech (Australia) Clinical implications of the FIELD study results V. Brown (USA) Diabetic retinopathy - New approaches to management P. Dodson (UK) |
12:30 p.m. 02:00 p.m. |
|
Lunch Debate sponsored by ASTRAZENECA Antiplatelet therapy: how to proceed with surgery or invasive diagnostic procedures? G. Thiefin (France), P. Albaladejo (France), |
02:00 p.m. 03:30 p.m. |
•
•
• |
FONDATION COEUR ET ARTERES - Symposium 1 Treatment of dyslipidemia in the metabolic syndrome Chairs: J. Betteridge (UK) - J. Davignon (Canada) Physiopathology of dyslipidemia in the metabolic syndrome M.-R. Taskinen (Finland) Low High Density Lipotein (HDL) and decrease of the cardiovascular risk in the metabolic syndrome E. J. Schaefer (USA) New strategies for rising HDL by modulating nuclear receptors J.-C. Fruchart (France) |
03:30 p.m. 04:00 p.m. |
|
Coffee Break |
04:00 p.m. 05:30 p.m. |
•
•
•
• |
SYMPOSIUM sponsored by KOWA Management of HDL-C - Experience with a new statin Chair: J.-C. Fruchart (France) Management of HDL-C in patients with metabolic syndrome (type 2 Diabetes) A. Steinmetz (Germany) Comparative trial on the effects of pitavastatin and atorvastatin on HDL- cholesterol levels and safety in patients with elevated LDL-cholesterol and glucose intolerance: the PIAT study J. Sasaki (Japan) Pitavastatin; pooled-analysis of EU and US studies J. Kastelein (The Netherlands) Closing remarks J.-C. Fruchart (France) |
Program |
